Literature DB >> 12556427

The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae.

K P Klugman1.   

Abstract

A small number of pneumococcal clones dominate the population of antibiotic-resistant pneumococci. The emergence of fluoroquinolone resistance in these clones predicts the dissemination of fluoroquinolone resistance in countries where the clones are present and community use of fluoroquinolones for respiratory infections is common. The molecular basis of resistance to a number of classes of antimicrobials can be used to predict the likelihood of dissemination of the resistance genes.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12556427     DOI： 10.1093/jac/dkf500

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  26 in total

1.  Multidrug-resistant Streptococcus pneumoniae serotype 6D clones in South Korea.

Authors:  Kwan Soo Ko; Jin Yang Baek; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007.

Authors:  Ana Paula de O Menezes; Leila C Campos; Milena S dos Santos; Jailton Azevedo; Renan C N Dos Santos; Maria da Gloria S Carvalho; Bernard W Beall; Stacey W Martin; Katia Salgado; Mitermayer G Reis; Albert I Ko; Joice N Reis
Journal:  Vaccine       Date:  2010-12-21       Impact factor: 3.641

3.  Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004.

Authors:  Andreas Kronenberg; Phillip Zucs; Sara Droz; Kathrin Mühlemann
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.

Authors:  R Dias; M Caniça
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

6.  Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.

Authors:  Kimberly A Nichol; Heather J Adam; James A Karlowsky; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

7.  Molecular characterization of pneumococci with efflux-mediated erythromycin resistance and identification of a novel mef gene subclass, mef(I).

Authors:  Ileana Cochetti; Manuela Vecchi; Marina Mingoia; Emily Tili; Maria R Catania; Aldo Manzin; Pietro E Varaldo; Maria Pia Montanari
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  International pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance.

Authors:  Daniel Rudolf; Nikolay Michaylov; Mark van der Linden; Ludwig Hoy; Keith P Klugman; Tobias Welte; Mathias W Pletz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

9.  A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.

Authors:  Hansjürg Engel; Moana Mika; Dalia Denapaite; Regine Hakenbeck; Kathrin Mühlemann; Manfred Heller; Lucy J Hathaway; Markus Hilty
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

10.  Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.

Authors:  Mathias W R Pletz; Lesley McGee; James Jorgensen; Bernard Beall; Richard R Facklam; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.